NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE:FRX) announced today that FETZIMA™ (levomilnacipran ER capsules), is now available in pharmacies throughout the United States. FETZIMA was ...
ADDING MULTIMEDIA: Forest Laboratories and Pierre Fabre Laboratories Announce FDA Approval of FETZIM
In the placebo-controlled, pivotal Phase III studies of adult patients with MDD, statistically significant and clinically meaningful improvement in depressive symptoms (primary endpoint) was ...
NEW YORK & CASTRES, France--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) and Pierre Fabre Laboratories announced today that FETZIMA™ (levomilnacipran extended-release capsules), a once-daily ...
New Depression Drug Gets Green Light from FDA Fetzima (levomilnacipran extended-release capsules; Forest and Pierre Fabre) has been approved for the treatment of major depressive disorder in adults.
Forest Laboratories and Pierre Fabre Laboratories Announce FDA Approval of FETZIMA™ for the Treatment of Major Depressive Disorder in Adults NEW YORK & CASTRES, France--(BUSINESS WIRE)--Forest ...
ADDING MULTIMEDIA: Forest Laboratories and Pierre Fabre Laboratories Announce FDA Approval of FETZIM
ADDING MULTIMEDIA: Forest Laboratories and Pierre Fabre Laboratories Announce FDA Approval of FETZIMA™ for the Treatment of Major Depressive Disorder in Adults NEW YORK & CASTRES, France--(BUSINESS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results